Usefulness of non-invasive markers for predicting liver cirrhosis in patients with chronic hepatitis B

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 1, 2010, Pages 94-100

  Lee, Kwang Gyun ^a   Seo, Yeon Seok ^a   An, Hyonggin ^a   Um, Soon Ho ^a   Jung, Eun Suk ^a   Keum, Bora ^a   Yim, Hyung Joon ^a   Jeen, Yoon Tae ^a   Chun, Hoon Jai ^a   Kim, Chang Duck ^a   Ryu, Ho Sang ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Haptoglobin; Liver cirrhosis; Marker; Platelet

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; COLLAGEN TYPE 4; GELATINASE A; HAPTOGLOBIN; HYALURONIC ACID;

ACCURACY; ADULT; ARTICLE; BLOOD CELL; CHRONIC HEPATITIS; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; LEUKOCYTE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; THROMBOCYTE COUNT;

EID: 73449128326     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.05953.x     Document Type: Article

References (45)

1. Naveau S, Poynard T, Benattar C, Bedossa P, Chaput JC. Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest. Dig. Dis. Sci. 1994 39 : 2426 2432.
2. Han YS, Kim BH, Baek IY et al. The change of the etiology, complications and causes of death of liver cirrhosis in 1990s. Korean J. Hepatol. 2000 6 : 328 329.
3. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002 36 : S152 60.
4. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000 32 : 477 481.
5. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N. Engl. J. Med. 2001 344 : 495 500.
6. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J. Hepatol. 2003 39 : 239 244.
7. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003 38 : 1449 1457. (Pubitemid 37466971)
8. Siddique I, El-Naga HA, Madda JP, Memon A, Hasan F. Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand. J. Gastroenterol. 2003 38 : 427 432.
9. Maharaj B, Maharaj RJ, Leary WP et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986 1 : 523 525.
10. Regev A, Berho M, Jeffers LJ et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am. J. Gastroenterol. 2002 97 : 2614 2618.
11. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994 20 : 15 20.
12. Vallet-Pichard A, Mallet V, Nalpas B et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007 46 : 32 6.
13. Parise ER, Oliveira AC, Figueiredo-Mendes C et al. Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver Int. 2006 26 : 1095 1099.
14. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am. J. Gastroenterol. 1998 93 : 44 8.
15. Poynard T, Aubert A, Bedossa P et al. A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology 1991 100 : 1397 1402.
16. Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J. Viral Hepat. 1997 4 : 199 208.
17. Forns X, Ampurdanes S, Llovet JM et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002 36 : 986 992.
18. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003 38 : 518 526.
19. Bonacini M, Hadi G, Govindarajan S, Lindsay KL. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am. J. Gastroenterol. 1997 92 : 1302 1304.
20. Hui AY, Chan HL, Wong VW et al. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am. J. Gastroenterol. 2005 100 : 616 623.
21. Schiavon LL, Narciso-Schiavon JL, Carvalho Filho RJ et al. Serum levels of YKL-40 and hyaluronic acid as noninvasive markers of liver fibrosis in haemodialysis patients with chronic hepatitis C virus infection. J. Viral Hepat. 2008 15 : 666 674.
22. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am. J. Gastroenterol. 2004 99 : 1160 1174.
23. Patel K, Muir AJ, McHutchison JG. Validation of a simple predictive model for the identification of mild hepatic fibrosis in chronic hepatitis C patients. Hepatology 2003 37 : 1222 author reply 1222-3.
24. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am. J. Surg. Pathol. 1995 19 : 1409 1417.
25. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983 148 : 839 843.
26. Afdhal NH. Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests? Hepatology 2003 37 : 972 974.
27. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001 357 : 1069 1075.
28. Khan JA, Khan FA, Dilawar M, Ijaz A, Khan NA, Mehmood T. Serum hyaluronic acid as a marker of hepatic fibrosis. J. Coll. Physicians Surg. Pak. 2007 17 : 323 326.
29. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as modulator of stellate cell and hepatic fibrogenesis. Semin Liver Dis. 2001 21 : 351 372.
30. Giannini EG, Zaman A, Ceppa P, Mastracci L, Risso D, Testa R. A simple approach to noninvasively identifying significant fibrosis in chronic hepatitis C patients in clinical practice. J. Clin. Gastroenterol. 2006 40 : 521 527.
31. Wright TL. Introduction to chronic hepatitis B infection. Am. J. Gastroenterol 2006 101 (Suppl. 1 S1 6.
32. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997 349 : 825 832.
33. Rozario R, Ramakrishna B. Histopathological study of chronic hepatitis B and C: a comparison of two scoring systems. J. Hepatol. 2003 38 : 223 229.
34. Bartos V, Krkoska D, Slavik P, Lauko L, Adamkov M. Histological status of the liver in relation to serum aminotransferase levels in patients with chronic hepatitis C. Bratisl. Lek. Listy 2007 108 : 522 525.
35. Cioni G, Tincani E, D'Alimonte P et al. Relevance of reduced portal flow velocity, low platelet count and enlarged spleen diameter in the non-invasive diagnosis of compensated liver cirrhosis. Eur. J. Med. 1993 2 : 408 410.
36. Poynard T, Zoulim F, Ratziu V et al. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am. J. Gastroenterol. 2005 100 : 1970 1980.
37. Sebastiani G, Vario A, Guido M, Alberti A. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J. Gastroenterol. 2007 13 : 525 531.
38. Myers RP, Tainturier MH, Ratziu V et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J. Hepatol. 2003 39 : 222 230. (Pubitemid 36920558)
39. Cales P, de Ledinghen V, Halfon P et al. Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int. 2008 28 : 1352 1362.
40. Poynard T, Munteanu M, Ngo Y et al. FibroTest is effective in patients with normal transaminases, when accuracy is standardized on fibrosis stage prevalence. J. Viral Hepat 2008 15 : 472 473. Author reply 474.
41. Morra R, Lebray P, Ingiliz P et al. FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C. Hepatology 2008 47 : 353 354. Author reply 354-6.
42. Fung J, Lai CL, Fong DY, Yuen JC, Wong DK, Yuen MF. Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis. Liver Int. 2008 28 : 1408 1416.
43. Pan JJ, Yang CF, Chu CJ, Chang FY, Lee SD. Prediction of liver fibrosis in patients with chronic hepatitis B by serum markers. Hepatogastroenterology 2007 54 : 1503 1506.
44. Kim BK, Kim SA, Park YN et al. Noninvasive models to predict liver cirrhosis in patients with chronic hepatitis B. Liver Int. 2007 27 : 969 976.
45. Sim SJ, Cheong JY, Cho SW et al. Efficacy of AST to platelet ratio index in predicting severe hepatic fibrosis and cirrhosis in chronic hepatitis B virus infection. Korean J. Gastroenterol. 2005 45 : 340 347.